Pharmacy Web Guide |
||||||||||||||||||||||||||||||||||||||||||||||||||
Our professional pharmacies was gratified with the order aptivus award. |
||||||||||||||||||||||||||||||||||||||||||||||||||
Order aptivus |
||||||||||||||||||||||||||||||||||||||||||||||||||
![]()
|
|
|
||||||||||||||||||||||||||||||||||||||||||||||||
Observational Non-interventional Field (anwendungsbeobachtung) With Aptivus(tipranavir) in Hiv-infected Patients. That discipline is currently recruiting participants. Verified by Boehringer Ingelheim Pharmaceuticals, November 2008 Sponsored by: Boehringer Ingelheim Pharmaceuticals Info provided by: Boehringer Ingelheim Pharmaceuticals Clinicaltrials.gov Identifier: NCT00531206 Conclusion That observational bailiwick is supposed to evaluate (under precondition of clinical drilling in daily routine) whether discussion with Aptivus (tipranavir) in combining with low-dose Norvir (ritonavir) leaving durably suppress viral lading and may achieve mash of viral payload below the boundary of detection. Consideration Phase HIV Infections Phase IV Medlineplus corresponding topics: AID Drugging Info available for: Ritonavir Tipranavir U.S. FDA Resources Subject Type: Observational Functionary Title: Observational Non-interventional Discipline Nearby Antiretroviral Compounding Sermon With Aptivus in Combining With Low-dose Ritonavir in HIV Geek 1 Infected Patients Besides subject item as provided by Boehringer Ingelheim Pharmaceuticals: Impelling Issue Measures: bingle Estimated Enrollment: 300 Estimated Subject Culmination Date: Apr 2009 Eligibility Ages Eligible for Study: 18 Days and elderly Genders Eligible for Study: Both Accepts Fit Volunteers: No Criteria Comprehension Criteria: Highly pre-treated male and female grownup patients with virus solid to multiple proteinase inhibitors. Aptivus (tipranavir), co-administered with low dosage Norvir (ritonavir), is attestanted for compounding antiretroviral preaching of HIV-1 transmission in highly pre-treated grownup patients with virus molded to multiple proteinase inhibitors. Animadversion Criteria: Age < 18 day pregnant female patients Hypersensitivity to the sharp capacity or to any of the excipients. Patients with moderationist or strict (child-pugh B or C) hepatic impairment. Rifampicin want not be used with Aptivus (tipranavir) now co-administration may causa laboured decreases in tipranavir concentrations which may in routine significantly diminution the tipranavir therapeutic effect. Herbal preparations containing St John's wort ought not be used go pickings Aptivus (tipranavir) due to the risk of decreased plasma concentrations and circumcised clinical burden of tipranavir. Co-administration of Aptivus (tipranavir) with low dosage Norvir (ritonavir), with wired substances this are highly drug-addicted on CYP3A for headroom and for which great plasma concentrations are germane with important and/or life-threatening events is contraindicated. These heedful substances include antiarrhythmics (amiodarone, bepridil, quinidine), antihistamines (astemizole, terfenadine), ergot derivatives (dihydroergotamine, ergonovine, ergotamine, methylergonovine), gastrointestinal motility agents (cisapride), neuroleptics (pimozide, sertindole), sedatives/hypnotics (triazolam) and Hmg-coa reductase inhibitors (simvastatin and lovastatin). In addition, co-administration of Aptivus (tipranavir) with low dosage Norvir (ritonavir), with drugs this are highly drug-addicted on CYP2D6 for clearance, such as the antiarrhythmics tambocor and propafenone, is contraindicated. |
||||||||||||||||||||||||||||||||||||||||||||||||||
| ... | ||||||||||||||||||||||||||||||||||||||||||||||||||